The FDA will provide faster regulatory review of generic drugs that are tested in and manufactured in the U.S. using domestically sourced active pharmaceutical ingredients. This FDA pilot program is part of a broader Trump administration strategy to reshore pharmaceutical production.Big pharmaceutical companies are boosting their production capacity of branded pharmaceutical products with billions of […]
